Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • 3.36% of about 82,600...

    3.36% of about 82,600 drugs samples found to be substandard

    Farhat NasimWritten by Farhat Nasim Published On 2018-12-21T10:00:41+05:30  |  Updated On 21 Dec 2018 10:00 AM IST
    3.36% of about 82,600 drugs samples found to be substandard

    Of the total, 236 drugs samples or 0.28 per cent were declared spurious or adulterated, Minister of State Chemicals and Fertilisers Mansukh L Mandaviya told the Lok Sabha.


    New Delhi: As many as 2,783 samples or 3.36 per cent of the total 82,599 samples tested by drug controllers of various states and Union Territories in 2017-18 were declared substandard, Parliament was informed Tuesday.


    Of the total, 236 samples or 0.28 per cent were declared spurious or adulterated, Minister of State Chemicals and Fertilisers Mansukh L Mandaviya told the Lok Sabha.


    In a written reply, Mandaviya said 2,783 samples of drugs were "declared not of standard quality" out of 82,599 samples tested, which is 3.36 per cent of the total.


    In 2016-17, the total number of drugs samples tested was 76,721, of which 2,780 were declared not of standard quality, at 3.6 per cent of the total, while 123 samples were found to be adulterated/spurious, the minister added.


    Stating that the government has taken various steps to curb the menace of substandard/spurious drugs, he said stringent penalties for manufacturing spurious drugs have been provided under the amended Drugs and Cosmetics Act, 2008.


    "Certain offences have also been made cognizable and non-bailable," Mandaviya, who is also Minister of State for Road Transport and Highways and Shipping, added.


    Moreover, the Cabinet Committee on Economic Affairs (CCEA) has also approved a proposal for strengthening the drug regulatory system in India both under the Centre and States at a total expenditure of Rs 1,750 crore.


    "Out of this, Rs 850 crore is the central government's share," Mandaviya said, adding the share of the Centre and states is 60:40 for all states except Jammu and Kashmir, Himachal Pradesh, Uttarakhand, Sikkim and North-Eastern states for which the ratio will be 90:10.


    Replying to another query, Mandaviya said fixing of ceiling prices of 856 essential medicines by National Pharmaceutical Pricing Authority (NPPA) has resulted in a saving of Rs 11,462 crore as on November 30, 2018.


    He further said the NPPA has been closely watching availability of coronary stents after fixing ceiling prices.


    "No shortage has been reported so far in this regard," the minister said.


    Also Read: Fake, low quality drugs come at high cost

    adulteratedcabinet committeeCCEADrug Controllerdrugs sampleseconomic afffairsexpired drugsfake drugshigh costLok Sabhalow quality drugsMansukh L Mandaviyamedicine samplesministry of chemical n fertiliserNPPASpurioussub standardtests
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok